Myrexis, Inc.
🏢 View company profile →12Patents
12Active
12Granted
49Portfolio score
Filing activity: Dec 20, 2002 → May 6, 2010 · 11 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8258145B2 | Method of treating brain cancer | Human Necessities | 7 | Active |
| US7989462B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | Chemistry; Metallurgy | 2 | Active |
| US7943146B2 | Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface | Chemistry; Metallurgy | 2 | Active |
| US7799768B2 | Polymorphs of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid di-N-methyl-D-glucamine | Human Necessities | 1 | Active |
| US9505800B2 | Extended triterpene derivatives | Chemistry; Metallurgy | 1 | Active |
| US7842805B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | Chemistry; Metallurgy | 0 | Active |
| US7816099B1 | Enzyme assay and use thereof | Physics | 0 | Active |
| US8476285B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | Chemistry; Metallurgy | 0 | Active |
| US8217073B2 | Pyrrole derivatives as therapeutic compounds | Chemistry; Metallurgy | 0 | Active |
| US8017780B1 | Therapeutic compounds and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US8309562B2 | Compounds and therapeutical use thereof | Chemistry; Metallurgy | 0 | Active |
| US8318425B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.